FR2603107B1 - Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus - Google Patents

Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus

Info

Publication number
FR2603107B1
FR2603107B1 FR878711736A FR8711736A FR2603107B1 FR 2603107 B1 FR2603107 B1 FR 2603107B1 FR 878711736 A FR878711736 A FR 878711736A FR 8711736 A FR8711736 A FR 8711736A FR 2603107 B1 FR2603107 B1 FR 2603107B1
Authority
FR
France
Prior art keywords
virus
vaccine
diagnosing
compositions
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR878711736A
Other languages
English (en)
Other versions
FR2603107A1 (fr
Inventor
Mary Kathleen Shriver
Elaine K Thomas
Wesley L Cosand
Larry H Gosting
Edna S Dickinson
Janela Mcclure
George J Todaro
Robert C Nowinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Systems Corp
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of FR2603107A1 publication Critical patent/FR2603107A1/fr
Application granted granted Critical
Publication of FR2603107B1 publication Critical patent/FR2603107B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B25/00—Multi-stage pumps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mechanical Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR878711736A 1986-08-20 1987-08-19 Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus Expired - Fee Related FR2603107B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89827386A 1986-08-20 1986-08-20
US4502687A 1987-05-01 1987-05-01
US6799687A 1987-06-29 1987-06-29

Publications (2)

Publication Number Publication Date
FR2603107A1 FR2603107A1 (fr) 1988-02-26
FR2603107B1 true FR2603107B1 (fr) 1992-04-24

Family

ID=27366600

Family Applications (1)

Application Number Title Priority Date Filing Date
FR878711736A Expired - Fee Related FR2603107B1 (fr) 1986-08-20 1987-08-19 Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus

Country Status (28)

Country Link
JP (1) JPS6485928A (fr)
KR (1) KR920008744B1 (fr)
AT (1) AT398080B (fr)
AU (1) AU616156B2 (fr)
BE (1) BE1000811A4 (fr)
CH (1) CH675728A5 (fr)
CS (1) CS275838B6 (fr)
DE (1) DE3727703A1 (fr)
DK (1) DK433087A (fr)
ES (1) ES2010727A6 (fr)
FI (1) FI873553A (fr)
FR (1) FR2603107B1 (fr)
GB (1) GB2196634B (fr)
GR (1) GR871298B (fr)
HU (1) HU214439B (fr)
IE (1) IE60671B1 (fr)
IL (1) IL83580A (fr)
IT (1) IT1222518B (fr)
LU (1) LU86972A1 (fr)
NL (1) NL8701950A (fr)
NO (2) NO300462B1 (fr)
NZ (1) NZ221440A (fr)
OA (1) OA08652A (fr)
PL (1) PL155084B1 (fr)
PT (1) PT85567B (fr)
SE (1) SE506025C2 (fr)
YU (1) YU152587A (fr)
ZW (1) ZW15487A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP96A (en) * 1986-06-03 1990-08-12 The Usa Dept Of Commerce Small peptides which inhibit binding to T-4 receptors and act as immunogens.
AU625720B2 (en) * 1987-05-01 1992-07-16 Genetic Systems Corporation Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
JP2520464B2 (ja) * 1987-05-29 1996-07-31 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ―１を中和するモノクロ―ナル抗体
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
JP2569185B2 (ja) * 1988-01-26 1997-01-08 アメリカ合衆国 抗ｈｉｖ応答を喚起する合成抗原
CA1341285C (fr) * 1988-02-12 2001-08-14 Chang Yi Wang Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
FR2632310B1 (fr) * 1988-06-06 1992-04-10 Pasteur Institut Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
JPH04502760A (ja) * 1988-10-03 1992-05-21 レプリゲン・コーポレーション エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
EP0421626A1 (fr) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccin contre le SIDA et l'hépatite B
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
SE468168B (sv) * 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
CA2047078A1 (fr) * 1990-07-19 1992-01-20 Steven S. Bondy Peptides cycliques neutralisant le vih
CA2047042A1 (fr) * 1990-07-19 1992-01-20 John Hannah Peptides cycliques neutralisant le vih
JPH05310785A (ja) * 1991-09-30 1993-11-22 Nitto Denko Corp Ｈｉｖ関連環状ペプチドおよびこれを固定化した吸着体
ES2149203T3 (es) * 1992-03-27 2000-11-01 Advanced Immunit T Inc Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple.
DK2783697T3 (en) 2005-12-09 2017-04-10 Vectus Biosystems Ltd VIP Fragments and uses thereof
JP5165751B2 (ja) 2008-09-02 2013-03-21 日本特殊陶業株式会社 スパークプラグ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341423C (fr) * 1984-10-31 2003-03-04 Paul A. Luciw Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
DE3650011T2 (de) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
WO1986006414A1 (fr) * 1985-04-29 1986-11-06 Genetic Systems Corporation Antigenes synthetiques permettant la detection d'une infection apparentee au sida
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
EP0245459B1 (fr) * 1985-11-07 1993-09-29 The President And Fellows Of Harvard College Proteine de cellules infectees par le virus lymphotrophique des cellules t, et son analyse
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
DK169582B1 (da) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
JPH0762031B2 (ja) * 1986-12-30 1995-07-05 アメリカ合衆国 エイズウイルスおよびエイズウイルスのタンパク質に対する細胞性免疫を誘導する合成ペプチド

Also Published As

Publication number Publication date
FI873553A0 (fi) 1987-08-17
DK433087D0 (da) 1987-08-19
SE506025C2 (sv) 1997-11-03
AU7720187A (en) 1988-05-19
KR920008744B1 (ko) 1992-10-09
HUT44619A (en) 1988-03-28
PL267401A1 (en) 1988-07-21
CS8706136A2 (en) 1990-08-14
SE8703225D0 (sv) 1987-08-19
PT85567B (pt) 1991-02-08
SE8703225L (sv) 1988-02-21
IT8721678A0 (it) 1987-08-19
GB2196634B (en) 1991-05-15
KR890002547A (ko) 1989-04-10
NL8701950A (nl) 1988-03-16
IT1222518B (it) 1990-09-05
AU616156B2 (en) 1991-10-24
CS275838B6 (en) 1992-03-18
ATA208987A (de) 1994-01-15
GB2196634A (en) 1988-05-05
JPS6485928A (en) 1989-03-30
NO934897L (no) 1993-12-29
NO873495D0 (no) 1987-08-19
NO934897D0 (no) 1993-12-29
FI873553A (fi) 1988-02-21
NO300462B1 (no) 1997-06-02
HU214439B (hu) 1998-03-30
NO873495L (no) 1988-02-22
OA08652A (fr) 1988-11-30
GR871298B (en) 1988-01-12
PT85567A (en) 1987-09-01
ZW15487A1 (en) 1988-09-14
GB8719587D0 (en) 1987-09-23
PL155084B1 (en) 1991-10-31
ES2010727A6 (es) 1989-12-01
FR2603107A1 (fr) 1988-02-26
IL83580A0 (en) 1988-01-31
CH675728A5 (fr) 1990-10-31
IE872219L (en) 1988-02-20
IL83580A (en) 1992-11-15
AT398080B (de) 1994-09-26
NZ221440A (en) 1991-11-26
BE1000811A4 (fr) 1989-04-11
YU152587A (sh) 1992-09-07
DK433087A (da) 1988-02-21
IE60671B1 (en) 1994-08-10
NO302176B1 (no) 1998-02-02
LU86972A1 (fr) 1988-03-02
DE3727703A1 (de) 1988-05-05

Similar Documents

Publication Publication Date Title
FR2603107B1 (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
BE835526A (fr) Procede de preparation d'agglomeres insonorisants, ainsi que les structures et panneaux formes a partir de ces agglomeres
FR2366310A1 (fr) Procede de preparation de corticosteroides
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
ES510042A0 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
EA199700413A1 (ru) Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
FR2376147A1 (fr) Prostaglandines bicycliques, utiles notamment comme anti-agglutinants des plaquettes sanguines et leur procede de preparation
BE777689A (fr) Nouveaux derives de l'imidazoline, compositions therapeutiques les contenant ainsi que le procede de preparation de ces derives et de ces compositions
UA45942A (uk) 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
BE898749A (fr) Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
FR2277891A1 (fr) Methode pour deceler par radio-immunometrie la presence d'anticorps de la blennorragie
FR2439194A1 (fr) Derives de la dibenzothiepine, leur procede de preparation et leur application therapeutique
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
FR2288724A1 (fr) Preparation de resorcinols a partir d'acides d-cetocarboxyliques ou de leurs lactones
DZ1407A1 (fr) Dérivés d-substitués des n,n'-ditriméthoxybenzoylepipérazine ainsi que leur procédé de préparation.
BE866475A (fr) Procede de preparation de composes du silicium presentant des groupes oximes lies au silicium par l'oxygene
BE830577A (fr) Derives actifs d'acide acetique, compositions therapeutiques les contenant ainsi que les procedes de preparation de ces derives et compositions
FR2619220B1 (fr) Antigenes specifiques de leishmania et leur procede de preparation, profils antigeniques contenant ces antigenes et leur application au diagnostic des leishmanioses viscerales.
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
DE3854857D1 (de) Verhütung und behandlung einer retrovirenkrankheit
FR2296640A1 (fr) Procede pour la preparation d'a-bromoisopropylidene 1a, 5a, 4-thia-2,6-diaza (3,2,0)-2 heptene-6 acetate 7-one ou de leurs esters
FR2599971B1 (fr) Procede d'obtention de modulateurs immunologiques pour le traitement de deficiences immunitaires provoquees par des virus, et produit ainsi obtenu
FR2358884A1 (fr) Compositions d'amino-alcools et leur procede de preparation et leur application notamment pour le traitement d'affections buccales

Legal Events

Date Code Title Description
ST Notification of lapse